# Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG

> **NCT04062656** · PHASE2 · UNKNOWN · sponsor: **University Hospital, Essen** · enrollment: 21 (actual)

## Conditions studied

- Gastric Cancer
- Adenocarcinoma of the Esophagogastric Junction

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** relatlimab
- **DRUG:** Oxaliplatin
- **DRUG:** Docetaxel
- **DRUG:** 5-Fluorouracil (5-FU)
- **DRUG:** Folic acid (FA)

## Key facts

- **NCT ID:** NCT04062656
- **Lead sponsor:** University Hospital, Essen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-26
- **Primary completion:** 2024-03
- **Final completion:** 2025-06-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04062656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04062656, "Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04062656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*